807 related articles for article (PubMed ID: 29084798)
1. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
2. Maintenance proton pump inhibition therapy and risk of oesophageal cancer.
Brusselaers N; Engstrand L; Lagergren J
Cancer Epidemiol; 2018 Apr; 53():172-177. PubMed ID: 29477057
[TBL] [Abstract][Full Text] [Related]
3. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.
Brusselaers N; Sadr-Azodi O; Engstrand L
J Gastroenterol; 2020 Apr; 55(4):453-461. PubMed ID: 31811561
[TBL] [Abstract][Full Text] [Related]
4. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden.
Brusselaers N; Lagergren J
BMJ Open; 2018 Jul; 8(7):e021869. PubMed ID: 29982219
[TBL] [Abstract][Full Text] [Related]
5. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
6. Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.
Waldum HL; Sørdal Ø; Fossmark R
Scand J Gastroenterol; 2018 Jun; 53(6):639-642. PubMed ID: 29852782
[TBL] [Abstract][Full Text] [Related]
7. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
Ngwenya S; Simin J; Brusselaers N
Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
[TBL] [Abstract][Full Text] [Related]
8. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
9. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.
García Rodríguez LA; Lagergren J; Lindblad M
Gut; 2006 Nov; 55(11):1538-44. PubMed ID: 16785284
[TBL] [Abstract][Full Text] [Related]
10.
Doorakkers E; Lagergren J; Engstrand L; Brusselaers N
Gut; 2018 Dec; 67(12):2092-2096. PubMed ID: 29382776
[TBL] [Abstract][Full Text] [Related]
11. Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy.
Holmberg D; Mattsson F; Xie S; Ness-Jensen E; El-Serag H; Lagergren J
J Gastroenterol; 2022 Dec; 57(12):942-951. PubMed ID: 36258093
[TBL] [Abstract][Full Text] [Related]
12. Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
Kamal H; Sadr-Azodi O; Engstrand L; Brusselaers N
Hepatology; 2021 Oct; 74(4):2021-2031. PubMed ID: 34018229
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
[TBL] [Abstract][Full Text] [Related]
14. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.
Brusselaers N; Lagergren J; Engstrand L
Cancer Epidemiol; 2019 Oct; 62():101585. PubMed ID: 31445426
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden.
Chandanos E; Lindblad M; Jia C; Rubio CA; Ye W; Lagergren J
Br J Cancer; 2006 Jul; 95(1):118-22. PubMed ID: 16755290
[TBL] [Abstract][Full Text] [Related]
16. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
17. Use of proton pump inhibitors for the risk of gastric cancer.
Gao H; Li L; Geng K; Teng C; Chen Y; Chu F; Zhao Y
Medicine (Baltimore); 2022 Dec; 101(49):e32228. PubMed ID: 36626449
[TBL] [Abstract][Full Text] [Related]
18. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
19. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions.
Song H; Zhu J; Lu D
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010623. PubMed ID: 25464111
[TBL] [Abstract][Full Text] [Related]
20. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer.
Farrow DC; Vaughan TL; Sweeney C; Gammon MD; Chow WH; Risch HA; Stanford JL; Hansten PD; Mayne ST; Schoenberg JB; Rotterdam H; Ahsan H; West AB; Dubrow R; Fraumeni JF; Blot WJ
Cancer Causes Control; 2000 Mar; 11(3):231-8. PubMed ID: 10782657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
